Drug Profile


Alternative Names: Erlosiban; OBE-001; Oxytocin antagonist - ObsEva

Latest Information Update: 02 Mar 2017

Price : $50

At a glance

  • Originator Merck Serono
  • Developer ObsEva
  • Class Oximes; Pyrrolidinones; Small molecules; Tocolytics
  • Mechanism of Action Oxytocin receptor antagonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity Yes

Highest Development Phases

  • Phase III Female infertility
  • Phase II Preterm labour

Most Recent Events

  • 22 Feb 2017 Phase-III clinical trials in Female infertility in Belgium (PO) (EudraCT2016-004266-25)
  • 17 Jan 2017 ObsEva terminates a phase II trial in Preterm labour in Belgium, Germany, Poland, Spain, Switzerland and the UK(NCT02326142)
  • 01 Dec 2016 ObsEva completes the phase II IMPLANT trial for Female infertility in Belgium, Czech Republic, Denmark, Poland, Spain and the UK (NCT02310802)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top